Metastatic Colorectal Cancer (mCRC) Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Metastatic Colorectal Cancer (mCRC) Epidemiology Forecast Report Coverage

Expert Market Research's “Metastatic Colorectal Cancer (mCRC) Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of metastatic colorectal cancer (mCRC). It projects the future incidence and prevalence rates of metastatic colorectal cancer (mCRC) cases across various populations. The study covers age, gender, and type as major determinants of the metastatic colorectal cancer (mCRC) population. The report highlights patterns in the prevalence of metastatic colorectal cancer (mCRC) over time and projects future trends based on multiple variables.

Metastatic Colorectal Cancer (mCRC) Understanding: Disease Overview

Metastatic colorectal cancer (mCRC) represents stage IV colorectal cancer in which malignant cells spread beyond the colon or rectum to distant organs, most commonly the liver, lungs, and peritoneum. It arises through progressive genetic mutations involving APC, KRAS, NRAS, BRAF, and mismatch repair pathways. Molecular profiling now plays a central role in classification and prognosis. Patients often present with systemic symptoms, organ-specific complications, or disease recurrence following earlier-stage treatment. Despite therapeutic advances, mCRC remains associated with substantial morbidity and mortality globally, particularly in aging populations.

Metastatic Colorectal Cancer (mCRC) Epidemiology Perspective

The metastatic colorectal cancer (mCRC) epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for metastatic colorectal cancer (mCRC) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for metastatic colorectal cancer (mCRC) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Colorectal cancer (CRC) is the third most common cancer worldwide, accounting for about 1.93 million new cases in 2022. Approximately 15-20% of CRC diagnoses present as metastatic (stage IV) at diagnosis.
• Estimates place metastatic cases around 500,000 globally, with an age-standardized incidence near 12-18.5 per 100,000 people.
• CRC incidence increases sharply with age, with the majority of cases in individuals aged ≥50 years, peaking above 70 years. However, early-onset cases (<50) are rising in many regions, contributing to later metastatic occurrences.
• Worldwide, colorectal cancer occurs and causes death more often in men than in women, and metastatic cases show a similar pattern.

Read more about this report - Request a Free Sample

Country-wise Metastatic Colorectal Cancer (mCRC) Epidemiology

The metastatic colorectal cancer (mCRC) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

A country-level perspective on metastatic colorectal cancer (mCRC) highlights significant clinical burden in both the United States and the United Kingdom. In the United States, there were 147,931 new colorectal cancer cases in 2022, with approximately 20% diagnosed at the distant metastatic stage, predominantly affecting adults over 50, and showing a higher incidence in males. In the United Kingdom, approximately 30% of colorectal cancer patients are diagnosed with stage IV (metastatic) disease, with the liver and lungs as the most common metastatic sites. These trends emphasize the importance of targeted screening and effective management strategies.

Metastatic Colorectal Cancer (mCRC): Treatment Overview

Treatment of metastatic colorectal cancer is guided by molecular status, disease burden, and patient fitness. Standard regimens include combination chemotherapy such as FOLFOX or FOLFIRI, often paired with targeted agents including anti-VEGF therapies or anti-EGFR monoclonal antibodies, in RAS wild-type disease. Immunotherapy with checkpoint inhibitors is effective in MSI-H or dMMR tumors. Surgical resection or ablation may be considered in oligometastatic disease, particularly liver-limited cases. Emerging strategies include HER2-targeted therapy and KRAS G12C inhibitors, expanding precision-driven treatment approaches.

Key Questions Answered

• What are the key findings of metastatic colorectal cancer (mCRC) epidemiology in the 8 major markets?
• What will be the total number of patients with metastatic colorectal cancer (mCRC) across the 8 major markets during the forecast period?
• What was the country-wise metastatic colorectal cancer (mCRC) epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of metastatic colorectal cancer (mCRC) patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of metastatic colorectal cancer (mCRC) during the forecast period of 2026-2035?
• What are the currently available treatments for metastatic colorectal cancer (mCRC)?
• What are the disease risks, signs, symptoms, and unmet needs of metastatic colorectal cancer (mCRC)?

Scope of the Metastatic Colorectal Cancer (mCRC) Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of metastatic colorectal cancer (mCRC) based on several factors.
• Metastatic Colorectal Cancer (mCRC) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The metastatic colorectal cancer (mCRC) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Colorectal Cancer Drug Pipeline Analysis Report

Colorectal Cancer Epidemiology Forecast